AHZANTIVE

AfliberceptMonographZiv-afliberceptMonograph USDailyMed:Aflibercept AU:DNot recommended L01XX44(WHO)S01LA05(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 862111-32-8N DB08885Y none 15C2VL427D D09574Y ChEMBL1742982 Aflibercept, sold under the brand namesEyleaandZaltrapamong others, is a medication used to treatwet macular degenerationand metastaticcolorectal cancer.It was developed byRegeneron Pharmaceuticals. It is an inhibitor ofvascular endothelial growth factor(VEGF).Aflibercept is a recombinant fusion protein consisting of the extracellular domains of human VEGF receptor 1 and 2 fused to the Fc portion of human IgG1.By acting as a soluble decoy for the natural VEGF receptors, aflibercept inhibits their activation, thereby reducing angiogenesis.